Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Recombinant human erythropoietin therapy has beneficial cardio-renal effects on moderate stages of chronic renal failure in the rat
Publication

Publications

Recombinant human erythropoietin therapy has beneficial cardio-renal effects on moderate stages of chronic renal failure in the rat

Title
Recombinant human erythropoietin therapy has beneficial cardio-renal effects on moderate stages of chronic renal failure in the rat
Type
Article in International Conference Proceedings Book
Year
2009
Authors
Garrido, P
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Reis, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Teixeira Lemos, E
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Costa, E
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Parada, B
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Piloto, N
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Sereno, J
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Teixeira, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Pinto, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Figueiredo, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Alves, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Rocha Pereira, P
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Belo, L
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Santos Silva, A
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Teixeira, F
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Conference proceedings International
Pages: 177-180
9th Congress of the European-Association-for-Clinical-Pharmacology-and-Therapeutics (EACPT)
Edinburgh, SCOTLAND, JUL 12-15, 2009
Indexing
Publicação em ISI Web of Knowledge ISI Web of Knowledge - 0 Citations
Scientific classification
FOS: Medical and Health sciences > Basic medicine
Other information
Authenticus ID: P-003-T0T
Abstract (EN): This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal model of moderate chronic renal failure (CRF). Four groups (n=7) of male rat were evaluated during a 12-week follow up period: control: rhEPO: 50 IU/Kg/wk. CRF: two stage 3/4 nephrectomy. CRF+ rhEPO (start after the 3rd wk of surgery). Renal function, haematology and serum inflammation and redox status were assessed. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also showing a proliferative and antioxidant action, due to increased serum TGF-beta 1 and decreased 3-NT. In conclusion, rhEPO therapy might be recommended in moderate CRF stages in order to efficiently correct not only the underlying anaemia but also the deleterious cardio-renal effects, due to a proliferative and antioxidant renoprotective action.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 4
Documents
We could not find any documents associated to the publication.
Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-09 at 06:03:43 | Privacy Policy | Personal Data Protection Policy | Whistleblowing